Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Sarcoma

1629MO - First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Date

18 Sep 2020

Session

Mini Oral - Sarcoma

Topics

Cytotoxic Therapy

Tumour Site

Soft Tissue Sarcomas

Presenters

Silvia Stacchiotti

Citation

Annals of Oncology (2020) 31 (suppl_4): S914-S933. 10.1016/annonc/annonc288

Authors

S. Stacchiotti1, W. Van der Graaf2, H. Doms3, R. Sanfilippo1, S.I. Marreaud3, W. Van Houdt4, I. Judson5, B. Kasper6, S. Litiere7, H. Gelderblom8

Author affiliations

  • 1 Adult Mesenchymal Tumor Medical Oncology Unit, Cancer Medicine Dpt, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 2 Cancer Medicine, Radboud University, 9103 6500 - Nijmegen/NL
  • 3 Na, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 4 Surgical Oncology, Nethrelands Cancer Institute, 121 1066 - Amsterdam/NL
  • 5 Retired From Sarcoma Unit 2017, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 6 Cancer Medicine, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 7 Department Of Statistics, European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 8 Medical Oncology Dept, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1629MO

Background

WD/DD LPS usually arises in the abdomen, while other LPS subtypes mainly have an extra-abdominal origin. With the lack of prospective data on anthracycline-based CT in advanced WD/DD LPS, we conducted a retrospective analysis of the activity of cytotoxic regimens in patients (pts) with LPS of intrabdominal origin (IA-LPS) who had entered EORTC/STBSG clinical studies, assuming that the vast majority of LPS at this location are WD/DD LPS.

Methods

We searched for all adult pts treated with first-line CT for advanced IA-LPS in EORTC/STBSG phase II-III trials from 1970. Treatment was aggregated into 5 groups: anthracycline (A) alone (Doxorubicin (D) 75 mg/m2, Caelyx 50 mg/m2, Epirubicin 75 mg/m2, Epirubicin 150 mg/m2), Ifosfamide (IFO) alone (IFO 5 g/m2, IFO 9 g/m2, IFO 12 g/m2), D+IFO (D 50 mg/m2+IFO 5 g/m2, D 75 mg/m2+IFO 5 g/m2, DOX 75 mg/m2+IFO 10 g/m2), D+cyclophosphamide+vincristine+DTIC (CYVADIC), “other” (brostallicin, trabectedin). Response was assessed by RECIST or WHO criteria. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method.

Results

109 IA-LPS pts from 13 trials, enrolled between 1978 and 2012, were identified (median age 57 yrs). Overall, there were 10/109 (9.2%) responders to CT: Table: 1629MO

Response TreatmentN (%) Total (N=109)
A alone (N=48) IFO alone (N=15) D+IFO (N=18) CYVADIC (N=8) Other (N=20)
CR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PR 3 (6.3) 2 (13.3) 4 (22.2) 1 (12.5) 0 (0.0) 10 (9.2)
SD 24 (50.0) 10 (66.7) 5 (27.8) 4 (50.0) 14 (70.0) 57 (52.3)
PD 20 (41.7) 3 (20.0) 6 (33.3) 3 (37.5) 6 (30.0) 38 (34.9)
Not evaluable 1 (2.1) 0 (0.0) 3 (16.7) 0 (0.0) 0 (0.0) 4 (3.7)
.

At 10-mo median follow-up (IQR 6-24), m-OS was 19 mos (95%CI 15-21), m-PFS 4 mos (95%CI 3-6). D+IFO achieved a not statistically significant longer m-PFS (12 mos) and m-OS (31 mos) than observed with other regimens. Univariate and multivariate analysis of response to CT did not identify prognostic factors.

Conclusions

Cytotoxic CT, in particular D alone, had limited activity in advanced IA-LPS. Though IFO-containing regimens showed higher activity compared to A alone in a small number of cases. This series provides a benchmark for future trials on new drugs in WD/DD LPS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

EORTC Soft Tissue and Bone Sarcoma Group.

Funding

Has not received any funding.

Disclosure

S. Stacchiotti, B. Kasper: Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pharmamar. R. Sanfilippo: Research grant/Funding (institution), Travel/Accommodation/Expenses: Pharmamar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.